Immunologix, DavosPharma In Antibody Pact

Immunologix and DavosPharma have formed a strategic alliance under which DavosPharma will represent and market human antibodies produced by Immunologix. Immunologix specializes in transforming naïve B-cells to produce 100% human monoclonal antibodies that can target all antigens including, cancer, viruses, bacteria, toxins and autoimmune diseases like diabetes, lupus, rheumatoid arthritis and multiple sclerosis. DavosPharma evaluates, coordinates and delivers chemistry through strategic partners to provide breakthrough solutions for drug development.

“The relationship between Immunologix and DavosPharma has been building since initial discussions began in December of 2010. We are extremely excited to partner with DavosPharma since they bring an experienced team of experts to Immunologix. The partnership allows both parties to offer their clients a platform to 100% human monoclonal antibody ready for clinical trials. It will help in bringing our game-changing technology to the pharmaceutical marketplace,” said Dr. Ryan Fiorini, founder and chief operating officer, Immunologix.

Barry Robins, president of DavosPharma, said, “The Immunologix platform of technology offers a new paradigm for therapeutic antibody discovery, development, and manufacturing. Our customers will understand that the ability to identify and produce a 100% human monoclonal antibody in less than six months with less adverse side effects is an extremely significant differentiator. The technology that we now offer through this strategic alliance will have an immediate impact on shorter development times, costs, and reduction of adverse effects due to immunogenicity.”